This compound is an amino-substituted quinazoline derivative used as a pharmaceutical intermediate in the manufacturing of afatinib-related impurities. It is characterized by the presence of aromatic rings, amine groups, and halogen atoms.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 1449430-53-8
(S)-N4-(3,4-Dichlorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine
pharmaceutical intermediate for afatinib impurities
7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
pharmaceutical intermediate
1-(1,1-Dimethylethyl) 2-ethyl (2S)-5-oxo-1,2-pyrrolidinedicarboxylate
Pharmaceutical intermediate for peptide synthesis
1-Boc-D-Pyroglutamic acid ethyl ester
Pharmaceutical intermediate
(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methoxy-4-oxobutanoic acid
Protected amino acid for peptide synthesis
(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-hydroxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide
active pharmaceutical ingredient
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine
Pharmaceutical intermediate for kinase inhibitors
Erlotinib hydrochloride
active pharmaceutical ingredient
6-amino-4-(3-chloro-4-fluoroanilino)quinazolin-7-ol
YEFNIUDZICAGOU-UHFFFAOYSA-N
C1=CC(=C(C=C1NC2=NC=NC3=CC(=C(C=C32)N)O)Cl)F